NHS to offer second dose of MenB vaccine after Kent outbreak

NHS Expands MenB Vaccination Programme Following Kent Outbreak

Following a meningitis B outbreak in Kent that claimed two lives and affected 19 others, the NHS will provide a second dose of the vaccine to more than 12,000 individuals who received the first round of inoculations. This initiative, which began next week, targets those potentially exposed to the bacteria, including students and schoolchildren in the region. Clinics will operate in Canterbury, Faversham, and Ashford, with online booking systems enabling eligible recipients to schedule appointments.

Targeted Rollout and Eligibility Criteria

The vaccination drive initially focused on students residing in university halls in Kent and individuals who frequented a nightclub linked to the outbreak. Subsequently, the scope was broadened to include sixth form students from schools or colleges where cases had been confirmed or suspected. NHS Kent and Medway confirmed that multiple clinics and hubs will host the second dose, with further details on registration expected to be released starting Monday.

“The outbreak represents an unprecedented situation, with a significant number of infections occurring rapidly,” stated Health Secretary Wes Streeting.

Two fatalities were reported: a 21-year-old university student, whose identity remains private, and Juliette Kenny, a sixth form pupil. Additional hospitalizations were also recorded. To manage the crisis, the UK Health Security Agency (UKHSA) classified the event as a national incident, facilitating the distribution of antibiotics and other resources.

Review of Teen Vaccination Policy

Initially, the MenB vaccination programme was limited to infants and young children, introduced in 2015. UK health advisers had previously determined that vaccinating teenagers was not cost-effective. However, the recent outbreak prompted Health Secretary Wes Streeting to request a reassessment from the Joint Committee on Vaccination and Immunisation (JCVI).

Preventative antibiotics were administered to a broader group, with long lines forming at the University of Kent over several days. The second dose of the MenB vaccine must be given at least four weeks after the first but can be delayed if necessary. The NHS emphasized that the vaccine safeguards against the majority of meningococcal group B strains prevalent in the UK.